Ribbon Acquisition Corp. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Ribbon Acquisition Corp. performed this year. My goal is to explain these filings in plain English so you can decide if this company fits your investment goals.

1. What does this company do?

Ribbon is a "blank check" company, also known as a SPAC. It was set up in the Cayman Islands to raise money through an IPO specifically to buy an existing business.

The Big News: Ribbon has agreed to merge with DRC Medicine Inc., a private company that makes AI-driven medical hardware and protective gear. Once the deal closes, Ribbon will stop being a shell company and become a public medical technology firm. DRC Medicine’s team will then take over operations.

2. Financial performance

As a shell company, Ribbon has no sales. The $690,000 profit reported for 2025 is interest earned on the $145 million sitting in their trust account.

The company spent $120,000 on legal fees, audits, and paperwork to pursue the merger. Because they have no income, they rely on the money raised in their IPO and potential loans from their sponsor to pay these bills.

3. Major wins and challenges

• The Win: Ribbon secured a merger agreement and received shareholder approval to extend their deadline. They now have until January 16, 2027, to finalize the deal.
• The Hurdle: Management identified a "material weakness" in their financial reporting, noting they currently lack the accounting staff needed to handle the complex rules of a public company. They plan to hire more staff and improve their accounting policies before the merger closes.

4. How the "Redemption" Process Works

If you don’t want to participate in the merger, you can redeem your shares for your portion of the cash in the trust account.

• The "Delivery" Requirement: You must choose to redeem and send your shares to the transfer agent, Continental Stock Transfer & Trust Company, at least two business days before the shareholder vote.
• The Cost: The transfer agent charges an $80 fee per transaction. Check with your broker to see if they will cover this fee, as it can eat into the value of smaller investments.
• The 15% Rule: No single investor or group can redeem more than 15% of the IPO shares. This prevents one large investor from pulling too much cash and killing the deal.

5. Key risks

• The "Going Concern" Warning: Auditors warned that if the merger isn't finished by January 16, 2027, the company must shut down and return the remaining cash to investors.
• The "Rights" Trap: If you hold "rights," they convert into 1/7th of a share only if the merger succeeds. If the deal fails, these rights become worthless.
• The $5M Floor: The merger requires at least $5,000,001 in net assets after all redemptions. If too many people redeem their shares, the deal will be canceled.

6. Future outlook

The company’s primary goal is to close the DRC Medicine merger. After that, the board will change. The current sponsor will pick one director, and DRC Medicine will pick the other four.

Final Thought for Investors: When deciding whether to hold or redeem, keep a close eye on the January 2027 deadline and the status of the "material weakness" in their accounting. Since the company’s value is currently tied to the cash in the trust, your main decision is whether you believe in the long-term potential of DRC Medicine’s AI-driven medical technology versus taking your cash back now.